{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:11:27Z","timestamp":1793945487486,"version":"4.8.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MC_U120097115"],"award-info":[{"award-number":["MC_U120097115"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W005557\/1"],"award-info":[{"award-number":["MR\/W005557\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V013734\/1"],"award-info":[{"award-number":["MR\/V013734\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["094849\/Z\/10\/Z"],"award-info":[{"award-number":["094849\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Synapses are implicated in many neuropsychiatric illnesses. Here, we provide an overview of in vivo techniques to index synaptic markers in patients. Several positron emission tomography (PET) tracers for synaptic vesicle glycoprotein 2\u2009A (SV2A) show good reliability and selectivity. We review over 50 clinical studies including over 1700 participants, and compare findings in healthy ageing and across disorders, including addiction, schizophrenia, depression, posttraumatic stress disorder, and neurodegenerative disorders, including tauopathies, Huntington\u2019s disease and \u03b1-synucleinopathies. These show lower SV2A measures in cortical brain regions across most of these disorders relative to healthy volunteers, with the most well-replicated findings in tauopathies, whilst changes in Huntington\u2019s chorea, Parkinson\u2019s disease, corticobasal degeneration and progressive supranuclear palsy are predominantly subcortical. SV2A PET measures are correlated with functional connectivity across brain networks, and a number of other measures of brain function, including glucose metabolism. However, the majority of studies found no relationship between grey matter volume measured with magnetic resonance imaging and SV2A PET measures. Cognitive dysfunction, in domains including working memory and executive function, show replicated inverse relationships with SV2A measures across diagnoses, and initial findings also suggest transdiagnostic relationships with mood and anxiety symptoms. This suggests that synaptic abnormalities could be a common pathophysiological substrate underlying cognitive and, potentially, affective symptoms. We consider limitations of evidence and future directions; highlighting the need to develop postsynaptic imaging markers and for longitudinal studies to test causal mechanisms.<\/jats:p>","DOI":"10.1038\/s41386-024-01943-x","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T15:02:19Z","timestamp":1723474939000},"page":"164-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Synaptic changes in psychiatric and neurological disorders: state-of-the art of in vivo imaging"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-1972","authenticated-orcid":false,"given":"Oliver","family":"Howes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3120-1816","authenticated-orcid":false,"given":"Julia","family":"Marcinkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3766-3815","authenticated-orcid":false,"given":"Federico E.","family":"Turkheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"1943_CR1","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.tics.2011.03.006","volume":"15","author":"DS Bassett","year":"2011","unstructured":"Bassett DS, Gazzaniga MS. Understanding complexity in the human brain. Trends Cogn Sci. 2011;15:200\u20139.","journal-title":"Trends Cogn Sci"},{"key":"1943_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/jnc.13713","volume":"138","author":"K Lepeta","year":"2016","unstructured":"Lepeta K, Lourenco MV, Schweitzer BC, Martino Adami PV, Banerjee P, Catuara-Solarz S, et al. Synaptopathies: synaptic dysfunction in neurological disorders\u2013A review from students to students. J Neurochem. 2016;138:785\u2013805.","journal-title":"J Neurochem"},{"key":"1943_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-018-0518-5","volume":"10","author":"X Wang","year":"2018","unstructured":"Wang X, Christian KM, Song H, Ming G-l. Synaptic dysfunction in complex psychiatric disorders: from genetics to mechanisms. Genome Med. 2018;10:1\u20133.","journal-title":"Genome Med"},{"key":"1943_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/BF02284844","volume":"25","author":"ME Calhoun","year":"1996","unstructured":"Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, Mouton PR. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol. 1996;25:821\u20138.","journal-title":"J Neurocytol"},{"key":"1943_CR5","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/0006-8993(90)91037-H","volume":"517","author":"TL Petit","year":"1990","unstructured":"Petit TL, LeBoutillier JC. Quantifying synaptic number and structure: effects of stain and post-mortem delay. Brain Res. 1990;517:269\u201375.","journal-title":"Brain Res"},{"key":"1943_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1017\/S1461145712000016","volume":"16","author":"V Duric","year":"2013","unstructured":"Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC, et al. Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. Int J Neuropsychopharmacol. 2013;16:69\u201382.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1943_CR7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00259-019-04488-0","volume":"47","author":"SP McCluskey","year":"2020","unstructured":"McCluskey SP, Plisson C, Rabiner EA, Howes O. Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. Eur J Nucl Med Mol imaging. 2020;47:451\u201389.","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1943_CR8","doi-asserted-by":"publisher","first-page":"864514","DOI":"10.3389\/fnins.2022.864514","volume":"16","author":"R Rossi","year":"2022","unstructured":"Rossi R, Arjmand S, B\u00e6rentzen SL, Gjedde A, Landau AM. Synaptic vesicle glycoprotein 2A: features and functions. Front Neurosci. 2022;16:864514.","journal-title":"Front Neurosci"},{"key":"1943_CR9","doi-asserted-by":"publisher","first-page":"102197","DOI":"10.1016\/j.arr.2024.102197","volume":"94","author":"M Visser","year":"2024","unstructured":"Visser M, O\u2019Brien JT, Mak E. In vivo imaging of synaptic density in neurodegenerative disorders with positron emission tomography: A systematic review. Ageing Res Rev. 2024;94:102197.","journal-title":"Ageing Res Rev"},{"key":"1943_CR10","doi-asserted-by":"publisher","first-page":"60S","DOI":"10.2967\/jnumed.121.263201","volume":"63","author":"RE Carson","year":"2022","unstructured":"Carson RE, Naganawa M, Toyonaga T, Koohsari S, Yang Y, Chen MK, et al. Imaging of synaptic density in neurodegenerative disorders. J Nucl Med. 2022;63:60S\u201367S.","journal-title":"J Nucl Med"},{"key":"1943_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1152\/physrev.1974.54.2.418","volume":"54","author":"K Krnjevi\u0107","year":"1974","unstructured":"Krnjevi\u0107 K. Chemical nature of synaptic transmission in vertebrates. Physiol Rev. 1974;54:418\u2013540.","journal-title":"Physiol Rev"},{"key":"1943_CR12","doi-asserted-by":"crossref","unstructured":"Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008;33:18\u201341.","DOI":"10.1038\/sj.npp.1301559"},{"key":"1943_CR13","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s11571-021-09679-w","volume":"15","author":"V Di Maio","year":"2021","unstructured":"Di Maio V. The glutamatergic synapse: a complex machinery for information processing. Cogn Neurodyn. 2021;15:757\u201381. https:\/\/doi.org\/10.1007\/s11571-021-09679-w","journal-title":"Cogn Neurodyn"},{"key":"1943_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/med.20187","volume":"31","author":"K Wimalasena","year":"2011","unstructured":"Wimalasena K. Vesicular monoamine transporters: Structure\u2010function, pharmacology, and medicinal chemistry. Medicinal Res Rev. 2011;31:483\u2013519.","journal-title":"Medicinal Res Rev"},{"key":"1943_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1126\/science.1589771","volume":"256","author":"N Brose","year":"1992","unstructured":"Brose N, Petrenko AG, S\u00fcdhof TC, Jahn R. Synaptotagmin: a calcium sensor on the synaptic vesicle surface. Science. 1992;256:1021\u20135.","journal-title":"Science"},{"key":"1943_CR16","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/0896-6273(94)90352-2","volume":"13","author":"J Pevsner","year":"1994","unstructured":"Pevsner J, Hsu S-C, Braun JE, Calakos N, Ting AE, Bennett MK, et al. Specificity and regulation of a synaptic vesicle docking complex. Neuron. 1994;13:353\u201361.","journal-title":"Neuron"},{"key":"1943_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/jnc.15499","volume":"159","author":"MA Cousin","year":"2021","unstructured":"Cousin MA. Synaptophysin\u2010dependent synaptobrevin\u20102 trafficking at the presynapse\u2010Mechanism and function. J Neurochem. 2021;159:78\u201389.","journal-title":"J Neurochem"},{"key":"1943_CR18","doi-asserted-by":"publisher","first-page":"796129","DOI":"10.3389\/fnins.2022.796129","volume":"16","author":"ME Serrano","year":"2022","unstructured":"Serrano ME, Kim E, Petrinovic MM, Turkheimer F, Cash D. Imaging synaptic density: the next holy grail of neuroscience? Front Neurosci. 2022;16:796129.","journal-title":"Front Neurosci"},{"key":"1943_CR19","doi-asserted-by":"publisher","first-page":"22157","DOI":"10.1002\/syn.22157","volume":"74","author":"K Varn\u00e4s","year":"2020","unstructured":"Varn\u00e4s K, Stepanov V, Halldin C. Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non\u2010human primate and human brain. Synapse. 2020;74:22157.","journal-title":"Synapse"},{"key":"1943_CR20","doi-asserted-by":"publisher","first-page":"C960","DOI":"10.1152\/ajpcell.00259.2010","volume":"299","author":"A Nowack","year":"2010","unstructured":"Nowack A, Yao J, Custer KL, Bajjalieh SM. SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol-Cell Physiol. 2010;299:C960\u20137.","journal-title":"Am J Physiol-Cell Physiol"},{"key":"1943_CR21","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1038\/sj.jcbfm.9600493","volume":"27","author":"RB Innis","year":"2007","unstructured":"Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR22","doi-asserted-by":"publisher","first-page":"9861","DOI":"10.1073\/pnas.0308208101","volume":"101","author":"BA Lynch","year":"2004","unstructured":"Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci. 2004;101:9861\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"1943_CR23","unstructured":"Cai H, Mangner T, Muzik O, Chugani H. Radiosynthesis and preliminary evaluation of 11C-levetiracetam for PET imaging of SV2A expression. Soc Nuclear Med. 2014; 55:1795."},{"key":"1943_CR24","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/cmdc.201300482","volume":"9","author":"J Mercier","year":"2014","unstructured":"Mercier J, Archen L, Bollu V, Carr\u00e9 S, Evrard Y, Jnoff E, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single\u2010digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014;9:693\u20138.","journal-title":"ChemMedChem"},{"key":"1943_CR25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.nucmedbio.2016.03.004","volume":"43","author":"S Estrada","year":"2016","unstructured":"Estrada S, Lubberink M, Thibblin A, Sprycha M, Buchanan T, Mestdagh N, et al. [11C] UCB-A, a novel PET tracer for synaptic vesicle protein 2 A. Nucl Med Biol. 2016;43:325\u201332.","journal-title":"Nucl Med Biol"},{"key":"1943_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2967\/jnumed.117.198317","volume":"59","author":"EA Rabiner","year":"2018","unstructured":"Rabiner EA. Imaging synaptic density: a different look at neurologic diseases. J Nucl Med. 2018;59:380\u20131.","journal-title":"J Nucl Med"},{"key":"1943_CR27","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2967\/jnumed.115.168179","volume":"57","author":"NB Nabulsi","year":"2016","unstructured":"Nabulsi NB, Mercier J, Holden D, Carr\u00e9 S, Najafzadeh S, Vandergeten MC, et al. Synthesis and preclinical evaluation of 11C-UCB-J as a PET tracer for imaging the synaptic vesicle glycoprotein 2A in the brain. J Nucl Med. 2016;57:777\u201384.","journal-title":"J Nucl Med"},{"key":"1943_CR28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1177\/0271678X20964248","volume":"41","author":"H Tuncel","year":"2021","unstructured":"Tuncel H, Boellaard R, Coomans EM, de Vries EF, Glaudemans AW, Feltes PK, et al. Kinetics and 28-day test\u2013retest repeatability and reproducibility of [11C] UCB-J PET brain imaging. J Cereb Blood Flow Metab. 2021;41:1338\u201350.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.2967\/jnumed.123.266470","volume":"65","author":"LR Drake","year":"2024","unstructured":"Drake LR, Wu Y, Naganawa M, Asch R, Zheng C, Najafzadeh S, et al. First-in-Human Study of 18F-SynVesT-2: An SV2A PET Imaging Probe with Fast Brain Kinetics and High Specific Binding. J Nucl Med. 2024;65:462\u20139.","journal-title":"J Nucl Med"},{"key":"1943_CR30","doi-asserted-by":"crossref","unstructured":"Cai Z, Drake L, Naganawa M, Najafzadeh S, Pracitto R, Lindemann M. et al. First-in-human study of [18F] SynVesT-2, a novel SV2A radioligand with fast kinetics and high specific binding signals. Soc Nuclear Med. 2020;61:462","DOI":"10.2967\/jnumed.123.266470"},{"key":"1943_CR31","doi-asserted-by":"crossref","unstructured":"Zheng C, Holden D, Zheng MQ, Pracitto R, Wilcox KC, Lindemann M, et al. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18 F] SDM-16. Eur J Nucl Med Mol Imaging. 2022:1\u201315.","DOI":"10.1101\/2021.06.25.449978"},{"key":"1943_CR32","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1111\/ene.15451","volume":"29","author":"Y Tang","year":"2022","unstructured":"Tang Y, Liu P, Li W, Liu Z, Zhou M, Li J, et al. Detection of changes in synaptic density in amyotrophic lateral sclerosis patients using 18F\u2010SynVesT\u20101 positron emission tomography. Eur J Neurol. 2022;29:2934\u201343.","journal-title":"Eur J Neurol"},{"key":"1943_CR33","doi-asserted-by":"crossref","unstructured":"Smart K, Uribe C, Desmond KL, Martin SL, Vasdev N, Strafella AP. Preliminary Assessment of Reference Region Quantification and Reduced Scanning Times for [18 F] SynVesT-1 PET in Parkinson\u2019s Disease. Mol Imaging. 2023;2023.","DOI":"10.1155\/2023\/1855985"},{"key":"1943_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00259-020-05149-3","volume":"48","author":"S Li","year":"2021","unstructured":"Li S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, et al. Assessment of test-retest reproducibility of [18 F] SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol Imaging. 2021;48:1327\u201338.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"1943_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2967\/jnumed.120.249144","volume":"62","author":"M Naganawa","year":"2021","unstructured":"Naganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, et al. First-in-human evaluation of 18F-SynVesT-1, a radioligand for PET imaging of synaptic vesicle glycoprotein 2A. J Nucl Med. 2021;62:561\u20137.","journal-title":"J Nucl Med"},{"issue":"16","key":"1943_CR36","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.3390\/cancers14163870","volume":"14","author":"J L\u00f6ffler","year":"2022","unstructured":"L\u00f6ffler J, Herrmann H, Scheidhauer E, Wirth M, Wasserloos A, Solbach C, et al. Blocking studies to evaluate receptor-specific radioligand binding in the CAM model by PET and MR imaging. Cancers. 2022;14:3870.","journal-title":"Cancers"},{"issue":"Aug","key":"1943_CR37","doi-asserted-by":"publisher","first-page":"4862","DOI":"10.2174\/0929867329666220329204054","volume":"29","author":"M Viviano","year":"2022","unstructured":"Viviano M, Barresi E, Sim\u00e9on FG, Costa B, Taliani S, Da Settimo F, et al. Essential Principles and Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging. Curr Med Chem. 2022;29:4862\u201390. https:\/\/doi.org\/10.2174\/0929867329666220329204054","journal-title":"Curr Med Chem"},{"key":"1943_CR38","doi-asserted-by":"crossref","unstructured":"Kaminski RM, Gillard M, Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. 2012. In: Jasper's Basic Mechanisms of the Epilepsies [Internet]. 4th edition. Bethesda (MD): National Center for Biotechnology Information (US); 2012.","DOI":"10.1093\/med\/9780199746545.003.0076"},{"key":"1943_CR39","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1021\/ml500285t","volume":"5","author":"H Cai","year":"2014","unstructured":"Cai H, Mangner TJ, Muzik O, Wang M-W, Chugani DC, Chugani HT. Radiosynthesis of 11C-levetiracetam: a potential marker for PET imaging of SV2A expression. ACS MedChem Lett. 2014;5:1152\u20135.","journal-title":"ACS MedChem Lett"},{"key":"1943_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","volume":"43","author":"E Lukyanetz","year":"2002","unstructured":"Lukyanetz E, Shkryl V, Kostyuk P. Selective blockade of N\u2010type calcium channels by levetiracetam. Epilepsia. 2002;43:9\u201318.","journal-title":"Epilepsia"},{"key":"1943_CR41","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1528-1167.2006.00973.x","volume":"48","author":"I Carunchio","year":"2007","unstructured":"Carunchio I, Pieri M, Ciotti MT, Albo F, Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia. 2007;48:654\u201362.","journal-title":"Epilepsia"},{"key":"1943_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664:36\u201344.","journal-title":"Eur J Pharmacol"},{"key":"1943_CR43","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.2967\/jnumed.113.136143","volume":"55","author":"GI Warnock","year":"2014","unstructured":"Warnock GI, Aerts J, Bahri MA, Bretin F, Lemaire C, Giacomelli F, et al. Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med. 2014;55:1336\u201341.","journal-title":"J Nucl Med"},{"key":"1943_CR44","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2967\/jnumed.118.223867","volume":"60","author":"T Toyonaga","year":"2019","unstructured":"Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, et al. In vivo synaptic density imaging with 11C-UCB-J detects treatment effects of saracatinib in a mouse model of Alzheimer disease. J Nucl Med. 2019;60:1780\u20136.","journal-title":"J Nucl Med"},{"key":"1943_CR45","doi-asserted-by":"crossref","unstructured":"Zheng C, Toyonaga T, Chen B, Nicholson L, Mennie W, Liu M, et al. Decreased synaptic vesicle glycoprotein A binding in a rodent model of familial Alzheimer\u2019s disease detected by [F] SDM. Cancer and Central Nervous System Disease Diagnosis and Treatment. 2023:136.","DOI":"10.3389\/fneur.2023.1045644"},{"key":"1943_CR46","doi-asserted-by":"publisher","first-page":"752594","DOI":"10.3389\/fnins.2021.752594","volume":"15","author":"R Sanchez-Varo","year":"2021","unstructured":"Sanchez-Varo R, Sanchez-Mejias E, Fernandez-Valenzuela JJ, De Castro V, Mejias-Ortega M, Gomez-Arboledas A, et al. Plaque-associated oligomeric amyloid-beta drives early synaptotoxicity in APP\/PS1 mice hippocampus: ultrastructural pathology analysis. Front Neurosci. 2021;15:752594.","journal-title":"Front Neurosci"},{"issue":"348","key":"1943_CR47","doi-asserted-by":"publisher","first-page":"348ra96","DOI":"10.1126\/scitranslmed.aaf6667","volume":"8","author":"SJ Finnema","year":"2016","unstructured":"Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, et al. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8:348ra96.","journal-title":"Sci Transl Med"},{"key":"1943_CR48","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s11307-020-01506-8","volume":"22","author":"MB Thomsen","year":"2020","unstructured":"Thomsen MB, Schacht AC, Alstrup AKO, Jacobsen J, Lillethorup TP, B\u00e6rentzen SL, et al. Preclinical PET Studies of [11 C] UCB-J Binding in Minipig Brain. Mol Imaging Biol. 2020;22:1290\u20131300.","journal-title":"Mol Imaging Biol"},{"issue":"5","key":"1943_CR49","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1177\/0271678X20946198","volume":"41","author":"K Smart","year":"2021","unstructured":"Smart K, Liu H, Matuskey D, Chen MK, Torres K, Nabulsi N, et al. Binding of the synaptic vesicle radiotracer [11C] UCB-J is unchanged during functional brain activation using a visual stimulation task. J Cereb Blood Flow Metab. 2021;41:1067\u201379.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1943_CR50","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2967\/jnumed.119.228080","volume":"61","author":"A Mansur","year":"2020","unstructured":"Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M, et al. Characterization of 3 PET tracers for quantification of mitochondrial and synaptic function in healthy human brain: 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J. J Nucl Med. 2020;61:96\u2013103.","journal-title":"J Nucl Med"},{"key":"1943_CR51","doi-asserted-by":"crossref","unstructured":"Toyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot JD, et al. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C] UCB-J. Eur J Nucl Med Mol Imaging. 2023:1-11.","DOI":"10.1007\/s00259-023-06487-8"},{"key":"1943_CR52","doi-asserted-by":"publisher","first-page":"1124254","DOI":"10.3389\/fnhum.2023.1124254","volume":"17","author":"XT Fang","year":"2023","unstructured":"Fang XT, Volpi T, Holmes SE, Esterlis I, Carson RE, Worhunsky PD. Linking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and 11C-UCB-J PET study. Front Hum Neurosci. 2023;17:1124254.","journal-title":"Front Hum Neurosci"},{"key":"1943_CR53","doi-asserted-by":"publisher","first-page":"117877","DOI":"10.1016\/j.neuroimage.2021.117877","volume":"232","author":"L Michiels","year":"2021","unstructured":"Michiels L, Delva A, van Aalst J, Ceccarini J, Vandenberghe W, Vandenbulcke M, et al. Synaptic density in healthy human aging is not influenced by age or sex: a 11C-UCB-J PET study. Neuroimage. 2021;232:117877.","journal-title":"Neuroimage"},{"key":"1943_CR54","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.nucmedbio.2022.06.007","volume":"112","author":"KB Andersen","year":"2022","unstructured":"Andersen KB, Hansen AK, Knudsen K, Schacht AC, Damholdt MF, Brooks DJ, et al. Healthy brain aging assessed with [18F] FDG and [11C] UCB-J PET. Nucl Med Biol. 2022;112:52\u20138.","journal-title":"Nucl Med Biol"},{"issue":"1","key":"1943_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14122-0","volume":"11","author":"EC Onwordi","year":"2020","unstructured":"Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel MC, Wells L, et al. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun. 2020;11:246.","journal-title":"Nat Commun"},{"key":"1943_CR56","first-page":"01353","volume":"S0006-3223","author":"EC Onwordi","year":"2023","unstructured":"Onwordi EC, Whitehurst T, Shatalina E, Mansur A, Arumuham A, Osugo M, et al. Synaptic Terminal Density Early in the Course of Schizophrenia: an in vivo UCB-J Positron Emission Tomographic Imaging Study of Synaptic Vesicle Glycoprotein 2A (SV2A). Biol Psychiatry 2023;S0006-3223:01353\u20137.","journal-title":"Biol Psychiatry"},{"key":"1943_CR57","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpsychires.2023.02.026","volume":"161","author":"JH Yoon","year":"2023","unstructured":"Yoon JH, Zhang Z, Mormino E, Davidzon G, Minzenberg MJ, Ballon J, et al. Reductions in synaptic marker SV2A in early-course Schizophrenia. J Psychiatr Res. 2023;161:213\u20137.","journal-title":"J Psychiatr Res"},{"key":"1943_CR58","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1038\/s41380-021-01184-0","volume":"26","author":"R Radhakrishnan","year":"2021","unstructured":"Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Mol Psychiatry. 2021;26:7690\u20138.","journal-title":"Mol Psychiatry"},{"key":"1943_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/jcbfm.2014.202","volume":"35","author":"CA Salinas","year":"2015","unstructured":"Salinas CA, Searle GE, Gunn RN. The Simplified Reference Tissue Model: Model Assumption Violations and Their Impact on Binding Potential. J Cereb Blood Flow Metab. 2015;35:304\u201311. https:\/\/doi.org\/10.1038\/jcbfm.2014.202","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR60","doi-asserted-by":"publisher","first-page":"113203","DOI":"10.1016\/j.bbr.2021.113203","volume":"405","author":"EF Halff","year":"2021","unstructured":"Halff EF, Cotel M-C, Natesan S, McQuade R, Ottley CJ, Srivastava DP, et al. Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behav Brain Res. 2021;405:113203.","journal-title":"Behav Brain Res"},{"key":"1943_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.euroneuro.2018.03.004","volume":"28","author":"M Takaki","year":"2018","unstructured":"Takaki M, Kodama M, Mizuki Y, Kawai H, Yoshimura B, Kishimoto M, et al. Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine. Eur Neuropsychopharmacol. 2018;28:610\u20139.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1943_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neuroscience.2016.08.055","volume":"337","author":"C Gottschling","year":"2016","unstructured":"Gottschling C, Geissler M, Springer G, Wolf R, Juckel G, Faissner A. First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses. Neuroscience. 2016;337:117\u201330.","journal-title":"Neuroscience"},{"key":"1943_CR63","doi-asserted-by":"publisher","first-page":"S121","DOI":"10.1016\/j.biopsych.2023.02.309","volume":"93","author":"TV Casteele","year":"2023","unstructured":"Casteele TV, Laroy M, Van Cauwenberge M, Koole M, Dupont P, Sunaert S, et al. 69. Lower Grey Matter Volume is not Related to Synaptic Density in Late Life Depression. Biol Psychiatry. 2023;93:S121\u20132.","journal-title":"Biol Psychiatry"},{"key":"1943_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09562-7","volume":"10","author":"SE Holmes","year":"2019","unstructured":"Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, et al. Lower synaptic density is associated with depression severity and network alterations. Nat Commun. 2019;10:1529.","journal-title":"Nat Commun"},{"key":"1943_CR65","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.acra.2011.10.008","volume":"19","author":"RK Doot","year":"2012","unstructured":"Doot RK, Kurland BF, Kinahan PE, Mankoff DA. Design considerations for using PET as a response measure in single site and multicenter clinical trials. Academic Radiol. 2012;19:184\u201390.","journal-title":"Academic Radiol"},{"key":"1943_CR66","doi-asserted-by":"crossref","unstructured":"Holmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, et al. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Mol Psychiatry. 2022;27:2273\u201381.","DOI":"10.1038\/s41380-022-01465-2"},{"key":"1943_CR67","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41386-021-01111-5","volume":"47","author":"RH Asch","year":"2022","unstructured":"Asch RH, Holmes SE, Jastreboff AM, Potenza MN, Baldassarri SR, Carson RE, et al. Lower synaptic density is associated with psychiatric and cognitive alterations in obesity. Neuropsychopharmacology. 2022;47:543\u201352.","journal-title":"Neuropsychopharmacology"},{"key":"1943_CR68","doi-asserted-by":"publisher","first-page":"13123","DOI":"10.1111\/adb.13123","volume":"27","author":"GA Angarita","year":"2022","unstructured":"Angarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li CR, et al. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C\u2010UCB\u2010J positron emission tomography study in humans. Addiction Biol. 2022;27:13123.","journal-title":"Addiction Biol"},{"key":"1943_CR69","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1038\/s41380-020-00891-4","volume":"26","author":"DC D'souza","year":"2021","unstructured":"D'souza DC, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, et al. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Mol Psychiatry. 2021;26:3192\u20133200.","journal-title":"Mol Psychiatry"},{"key":"1943_CR70","doi-asserted-by":"crossref","unstructured":"Hou J, Xiao Q, Zhou M, Xiao L, Yuan M, Zhong N, et al. Lower synaptic density associated with gaming disorder: an 18F-SynVesT-1 PET imaging study. General Psychiatry. 2023;36:e101112.","DOI":"10.1136\/gpsych-2023-101112"},{"key":"1943_CR71","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.neuron.2009.06.007","volume":"63","author":"YH Huang","year":"2009","unstructured":"Huang YH, Lin Y, Mu P, Lee BR, Brown TE, Wayman G, et al. In vivo cocaine experience generates silent synapses. Neuron. 2009;63:40\u20137.","journal-title":"Neuron"},{"key":"1943_CR72","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/nn.3533","volume":"16","author":"BR Lee","year":"2013","unstructured":"Lee BR, Ma Y-Y, Huang YH, Wang X, Otaka M, Ishikawa M, et al. Maturation of silent synapses in amygdala-accumbens projection contributes to incubation of cocaine craving. Nat Neurosci. 2013;16:1644\u201351.","journal-title":"Nat Neurosci"},{"key":"1943_CR73","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1176\/appi.ajp.162.8.1403","volume":"162","author":"PW Kalivas","year":"2005","unstructured":"Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403\u201313.","journal-title":"Am J Psychiatry"},{"key":"1943_CR74","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","volume":"75","author":"M-K Chen","year":"2018","unstructured":"Chen M-K, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, et al. Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging. JAMA Neurol. 2018;75:1215\u201324.","journal-title":"JAMA Neurol"},{"key":"1943_CR75","doi-asserted-by":"publisher","first-page":"118248","DOI":"10.1016\/j.neuroimage.2021.118248","volume":"238","author":"Y Lu","year":"2021","unstructured":"Lu Y, Toyonaga T, Naganawa M, Gallezot JD, Chen MK, Mecca AP, et al. Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer\u2019s disease. Neuroimage. 2021;238:118248.","journal-title":"Neuroimage"},{"key":"1943_CR76","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1177\/0271678X211004312","volume":"41","author":"M-K Chen","year":"2021","unstructured":"Chen M-K, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, et al. Comparison of [11C] UCB-J and [18F] FDG PET in Alzheimer\u2019s disease: a tracer kinetic modeling study. J Cereb Blood Flow Metab. 2021;41:2395\u2013409.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR77","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/alz.12097","volume":"16","author":"AP Mecca","year":"2020","unstructured":"Mecca AP, Chen MK, O'dell RS, Naganawa M, Toyonaga T, Godek TA, et al. In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET. Alzheimer\u2019s Dement. 2020;16:974\u201382.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1943_CR78","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1007\/s00259-019-04461-x","volume":"47","author":"C Bastin","year":"2020","unstructured":"Bastin C, Bahri MA, Meyer F, Manard M, Delhaye E, Plenevaux A, et al. In vivo imaging of synaptic loss in Alzheimer\u2019s disease with [18F] UCB-H positron emission tomography. Eur J Nucl Med Mol imaging. 2020;47:390\u2013402.","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1943_CR79","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1038\/s41380-022-01672-x","volume":"27","author":"G Vanderlinden","year":"2022","unstructured":"Vanderlinden G, Ceccarini J, Vande Casteele T, Michiels L, Lemmens R, Triau E, et al. Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern. Mol Psychiatry. 2022;27:4244\u201351.","journal-title":"Mol Psychiatry"},{"key":"1943_CR80","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1212\/WNL.0000000000009818","volume":"95","author":"H Vanhaute","year":"2020","unstructured":"Vanhaute H, Ceccarini J, Michiels L, Koole M, Sunaert S, Lemmens R, et al. In vivo synaptic density loss is related to tau deposition in amnestic mild cognitive impairment. Neurology. 2020;95:e545\u201353.","journal-title":"Neurology"},{"key":"1943_CR81","doi-asserted-by":"publisher","unstructured":"Venkataraman AV, Bishop C, Mansur A, Rizzo G, Lewis Y, Kocagoncu E. et al. Imaging synaptic microstructure and synaptic loss in vivo in early Alzheimer\u2019s Disease. medRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.11.23.21266746.","DOI":"10.1101\/2021.11.23.21266746"},{"key":"1943_CR82","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1177\/0271678X231153730","volume":"43","author":"J Zhang","year":"2023","unstructured":"Zhang J, Wang J, Xu X, You Z, Huang Q, Huang Y, et al. In vivo synaptic density loss correlates with impaired functional and related structural connectivity in Alzheimer\u2019s disease. J Cereb Blood Flow Metab. 2023;43:977\u201388.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neurobiolaging.2023.08.001","volume":"132","author":"S Moallemian","year":"2023","unstructured":"Moallemian S, Salmon E, Bahri MA, Beliy N, Delhaye E, Balteau E, et al. Multimodal imaging of microstructural cerebral alterations and loss of synaptic density in Alzheimer\u2019s disease. Neurobiol Aging. 2023;132:24\u201335.","journal-title":"Neurobiol Aging"},{"key":"1943_CR84","doi-asserted-by":"crossref","unstructured":"O\u2019Dell RS, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, et al. Association of A\u03b2 deposition and regional synaptic density in early Alzheimer\u2019s disease: a PET imaging study with [11 C] UCB-J. Alzheimer\u2019s Research & Therapy. 2021;13:1\u20132.","DOI":"10.1186\/s13195-020-00742-y"},{"key":"1943_CR85","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1093\/brain\/awab282","volume":"145","author":"N Holland","year":"2022","unstructured":"Holland N, Malpetti M, Rittman T, Mak EE, Passamonti L, Kaalund SS, et al. Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study. Brain. 2022;145:340\u20138.","journal-title":"Brain"},{"key":"1943_CR86","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1002\/mds.28188","volume":"35","author":"N Holland","year":"2020","unstructured":"Holland N, Jones PS, Savulich G, Wiggins JK, Hong YT, Fryer TD, et al. Synaptic loss in primary tauopathies revealed by [11C] UCB\u2010J positron emission tomography. Mov Disord. 2020;35:1834\u201342.","journal-title":"Mov Disord"},{"key":"1943_CR87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.neurobiolaging.2021.01.016","volume":"101","author":"E Mak","year":"2021","unstructured":"Mak E, Holland N, Jones PS, Savulich G, Low A, Malpetti M, et al. In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies. Neurobiol Aging. 2021;101:187\u201398.","journal-title":"Neurobiol Aging"},{"key":"1943_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-95499-1","volume":"11","author":"E Salmon","year":"2021","unstructured":"Salmon E, Bahri MA, Plenevaux A, Becker G, Seret A, Delhaye E, et al. In vivo exploration of synaptic projections in frontotemporal dementia. Sci Rep. 2021;11:16092.","journal-title":"Sci Rep"},{"key":"1943_CR89","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/ana.26543","volume":"93","author":"M Malpetti","year":"2023","unstructured":"Malpetti M, Jones PS, Cope TE, Holland N, Naessens M, Rouse MA, et al. Synaptic Loss in Frontotemporal Dementia Revealed by [11C] UCB\u2010J Positron Emission Tomography. Ann Neurol. 2023;93:142\u201354.","journal-title":"Ann Neurol"},{"key":"1943_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44307-7","volume":"14","author":"DJ Whiteside","year":"2023","unstructured":"Whiteside DJ, Holland N, Tsvetanov KA, Mak E, Malpetti M, Savulich G, et al. Synaptic density affects clinical severity via network dysfunction in syndromes associated with frontotemporal lobar degeneration. Nat Commun. 2023;14:8458.","journal-title":"Nat Commun"},{"key":"1943_CR91","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1002\/mds.29421","volume":"38","author":"N Holland","year":"2023","unstructured":"Holland N, Jones PS, Savulich G, Naessens M, Malpetti M, Whiteside DJ, et al. Longitudinal Synaptic Loss in Primary Tauopathies: An In Vivo [11C] UCB\u2010J Positron Emission Tomography Study. Mov Disord. 2023;38:1316\u20131326.","journal-title":"Mov Disord"},{"key":"1943_CR92","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45:384\u20139.","journal-title":"J Mol Neurosci"},{"key":"1943_CR93","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ana.25682","volume":"87","author":"D Matuskey","year":"2020","unstructured":"Matuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, et al. Synaptic changes in Parkinson disease assessed with in vivo imaging. Ann Neurol. 2020;87:329\u201338.","journal-title":"Ann Neurol"},{"key":"1943_CR94","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1002\/mds.28216","volume":"35","author":"A Delva","year":"2020","unstructured":"Delva A, Van Weehaeghe D, Koole M, Van Laere K, Vandenberghe W. Loss of presynaptic terminal integrity in the substantia nigra in early Parkinson\u2019s disease. Mov Disord. 2020;35:1977\u201386.","journal-title":"Mov Disord"},{"key":"1943_CR95","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/mds.28064","volume":"35","author":"H Wilson","year":"2020","unstructured":"Wilson H, Pagano G, de Natale ER, Mansur A, Caminiti SP, Polychronis S, et al. Mitochondrial complex 1, sigma 1, and synaptic vesicle 2A in early drug\u2010naive Parkinson\u2019s disease. Mov Disord. 2020;35:1416\u201327.","journal-title":"Mov Disord"},{"key":"1943_CR96","doi-asserted-by":"crossref","unstructured":"Andersen KB, Hansen AK, Schacht AC, Horsager J, Gottrup H, Klit H, et al. Synaptic Density and Glucose Consumption in Patients with Lewy Body Diseases: An [11C] UCB\u2010J and [18F] FDG PET Study. Mov Disord. 2023;38:796\u2013805","DOI":"10.1002\/mds.29375"},{"key":"1943_CR97","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/mds.29148","volume":"37","author":"A Delva","year":"2022","unstructured":"Delva A, Van Laere K, Vandenberghe W. Longitudinal positron emission tomography imaging of presynaptic terminals in early Parkinson\u2019s disease. Mov Disord. 2022;37:1883\u201392.","journal-title":"Mov Disord"},{"key":"1943_CR98","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.28617","volume":"36","author":"KB Andersen","year":"2021","unstructured":"Andersen KB, Hansen AK, Damholdt MF, Horsager J, Skjaerbaek C, Gottrup H, et al. Reduced synaptic density in patients with lewy body dementia: An [11C] UCB\u2010J PET imaging study. Mov Disord. 2021;36:2057\u201365.","journal-title":"Mov Disord"},{"key":"1943_CR99","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/mds.29570","volume":"38","author":"MGA Van Cauwenberge","year":"2023","unstructured":"Van Cauwenberge MGA, Delva A, Vande Casteele T, Laroy M, Radwan A, Vansteelandt K, et al. Mild Motor Signs in Healthy Aging Are Associated with Lower Synaptic Density in the Brain. Mov Disord. 2023;38:1786\u201394.","journal-title":"Mov Disord"},{"key":"1943_CR100","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/brain\/awu036","volume":"137","author":"A Hanganu","year":"2014","unstructured":"Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson\u2019s disease longitudinally. Brain. 2014;137:1120\u20139.","journal-title":"Brain"},{"key":"1943_CR101","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1212\/WNL.0000000000012969","volume":"98","author":"A Delva","year":"2022","unstructured":"Delva A, Michiels L, Koole M, Van Laere K, Vandenberghe W. Synaptic damage and its clinical correlates in people with early Huntington disease: a PET study. Neurology. 2022;98:e83\u201394.","journal-title":"Neurology"},{"key":"1943_CR102","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/mds.29501","volume":"38","author":"A Delva","year":"2023","unstructured":"Delva A, Van Laere K, Vandenberghe W. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington\u2019s Disease. Mov Disord. 2023;38:1515\u201326.","journal-title":"Mov Disord"},{"key":"1943_CR103","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1002\/alz.12582","volume":"18","author":"AP Mecca","year":"2022","unstructured":"Mecca AP, O'dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, et al. Synaptic density and cognitive performance in Alzheimer\u2019s disease: A PET imaging study with [11C] UCB\u2010J. Alzheimer\u2019s Dement. 2022;18:2527\u201336.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1943_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41824-020-00093-9","volume":"4","author":"N Nicastro","year":"2020","unstructured":"Nicastro N, Holland N, Savulich G, Carter SF, Mak E, Hong YT, et al. 11C-UCB-J synaptic PET and multimodal imaging in dementia with Lewy bodies. Eur J hybrid imaging. 2020;4:1\u20137.","journal-title":"Eur J hybrid imaging"},{"key":"1943_CR105","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti\u2010tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2:278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"key":"1943_CR106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41386-022-01426-x","volume":"48","author":"OD Howes","year":"2023","unstructured":"Howes OD, Cummings C, Chapman GE, Shatalina E. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. Neuropsychopharmacology. 2023;48:151\u201367.","journal-title":"Neuropsychopharmacology"},{"key":"1943_CR107","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.neuroimage.2012.03.072","volume":"61","author":"H Zhang","year":"2012","unstructured":"Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage. 2012;61:1000\u201316.","journal-title":"Neuroimage"},{"key":"1943_CR108","doi-asserted-by":"publisher","unstructured":"Onwordi EC, Whitehurst T, Mansur A, Statton B, Berry A, Quinlan M, et al. The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Transl Psychiatry. 2021;11:393. https:\/\/doi.org\/10.1038\/s41398-021-01515-3","DOI":"10.1038\/s41398-021-01515-3"},{"key":"1943_CR109","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pnmrs.2011.06.001","volume":"60","author":"NA Puts","year":"2012","unstructured":"Puts NA, Edden RA. In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc. 2012;60:29\u201341.","journal-title":"Prog Nucl Magn Reson Spectrosc"},{"key":"1943_CR110","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neurobiolaging.2021.11.004","volume":"111","author":"AP Mecca","year":"2022","unstructured":"Mecca AP, Chen M-K, O'dell RS, Naganawa M, Toyonaga T, Godek TA, et al. Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer\u2019s disease. Neurobiol Aging. 2022;111:44\u201353.","journal-title":"Neurobiol Aging"},{"key":"1943_CR111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-00736-w","volume":"13","author":"EM Coomans","year":"2021","unstructured":"Coomans EM, Schoonhoven DN, Tuncel H, Verfaillie SCJ, Wolters EE, Boellaard R, et al. In vivo tau pathology is associated with synaptic loss and altered synaptic function. Alzheimer\u2019s Res Ther. 2021;13:1\u201313.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1943_CR112","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/cne.23234","volume":"521","author":"KJ Kopeikina","year":"2013","unstructured":"Kopeikina KJ, Polydoro M, Tai HC, Yaeger E, Carlson GA, Pitstick R, et al. Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol. 2013;521:1334\u201353.","journal-title":"J Comp Neurol"},{"key":"1943_CR113","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.celrep.2017.03.013","volume":"18","author":"JS Jackson","year":"2017","unstructured":"Jackson JS, Witton J, Johnson JD, Ahmed Z, Ward M, Randall AD, et al. Altered synapse stability in the early stages of tauopathy. Cell Rep. 2017;18:3063\u20138.","journal-title":"Cell Rep"},{"key":"1943_CR114","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neuron.2018.10.014","volume":"100","author":"B Dejanovic","year":"2018","unstructured":"Dejanovic B, Huntley MA, De Mazi\u00e8re A, Meilandt WJ, Wu T, Srinivasan K, et al. Changes in the synaptic proteome in tauopathy and rescue of tau-induced synapse loss by C1q antibodies. Neuron. 2018;100:1322\u201336.e7.","journal-title":"Neuron"},{"key":"1943_CR115","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007;53:337\u201351.","journal-title":"Neuron"},{"key":"1943_CR116","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1111\/epi.16653","volume":"61","author":"SJ Finnema","year":"2020","unstructured":"Finnema SJ, Toyonaga T, Detyniecki K, Chen MK, Dias M, Wang Q, et al. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C] UCB\u2010J positron emission tomography study. Epilepsia. 2020;61:2183\u201393.","journal-title":"Epilepsia"},{"key":"1943_CR117","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.neuron.2012.08.019","volume":"75","author":"JJ Harris","year":"2012","unstructured":"Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012;75:762\u201377.","journal-title":"Neuron"},{"key":"1943_CR118","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.3390\/ijms23073627","volume":"23","author":"A Faria-Pereira","year":"2022","unstructured":"Faria-Pereira A, Morais VA. Synapses: The brain\u2019s energy-demanding sites. Int J Mol Sci. 2022;23:3627.","journal-title":"Int J Mol Sci"},{"key":"1943_CR119","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1749-6632.1999.tb07824.x","volume":"893","author":"MP Mattson","year":"1999","unstructured":"Mattson MP, Pedersen WA, Duan W, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer\u2019s and Parkinson\u2019s diseases. Ann N. Y Acad Sci. 1999;893:154\u201375.","journal-title":"Ann N. Y Acad Sci"},{"key":"1943_CR120","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/j.euroneuro.2012.10.018","volume":"23","author":"BP Godsil","year":"2013","unstructured":"Godsil BP, Kiss JP, Spedding M, Jay TM. The hippocampal\u2013prefrontal pathway: The weak link in psychiatric disorders? Eur Neuropsychopharmacol. 2013;23:1165\u201381.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1943_CR121","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fnsys.2015.00190","volume":"9","author":"T Sigurdsson","year":"2016","unstructured":"Sigurdsson T, Duvarci S. Hippocampal-prefrontal interactions in cognition, behavior and psychiatric disease. Front Syst Neurosci. 2016;9:190.","journal-title":"Front Syst Neurosci"},{"key":"1943_CR122","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00702-016-1510-0","volume":"123","author":"W Schultz","year":"2016","unstructured":"Schultz W. Reward functions of the basal ganglia. J Neural Transm. 2016;123:679\u201393.","journal-title":"J Neural Transm"},{"key":"1943_CR123","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neulet.2014.11.042","volume":"601","author":"CE Moyer","year":"2015","unstructured":"Moyer CE, Shelton MA, Sweet RA. Dendritic spine alterations in schizophrenia. Neurosci Lett. 2015;601:46\u201353.","journal-title":"Neurosci Lett"},{"key":"1943_CR124","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/(SICI)1097-4547(19990501)56:3<307::AID-JNR10>3.0.CO;2-3","volume":"56","author":"H Nakamura","year":"1999","unstructured":"Nakamura H, Kobayashi S, Ohashi Y, Ando S. Age\u2010changes of brain synapses and synaptic plasticity in response to an enriched environment. J Neurosci Res. 1999;56:307\u201315.","journal-title":"J Neurosci Res"},{"key":"1943_CR125","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s11064-020-03102-2","volume":"45","author":"H Wang","year":"2020","unstructured":"Wang H, Xu X, Xu X, Gao J, Zhang T. Enriched environment and social isolation affect cognition ability via altering excitatory and inhibitory synaptic density in mice hippocampus. Neurochem Res. 2020;45:2417\u201332.","journal-title":"Neurochem Res"},{"key":"1943_CR126","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neubiorev.2015.09.022","volume":"61","author":"G Rayner","year":"2016","unstructured":"Rayner G, Jackson G, Wilson S. Cognition-related brain networks underpin the symptoms of unipolar depression: evidence from a systematic review. Neurosci Biobehav Rev. 2016;61:53\u201365.","journal-title":"Neurosci Biobehav Rev"},{"key":"1943_CR127","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neubiorev.2018.11.005","volume":"96","author":"J Xu","year":"2019","unstructured":"Xu J, Van Dam NT, Feng C, Luo Y, Ai H, Gu R, et al. Anxious brain networks: A coordinate-based activation likelihood estimation meta-analysis of resting-state functional connectivity studies in anxiety. Neurosci Biobehav Rev. 2019;96:21\u201330.","journal-title":"Neurosci Biobehav Rev"},{"key":"1943_CR128","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s42003-023-04637-0","volume":"6","author":"X Wang","year":"2023","unstructured":"Wang X, Chang Z, Wang R. Opposite effects of positive and negative symptoms on resting-state brain networks in schizophrenia. Commun Biol. 2023;6:279.","journal-title":"Commun Biol"},{"key":"1943_CR129","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022288118","volume":"118","author":"R Wang","year":"2021","unstructured":"Wang R, Liu M, Cheng X, Wu Y, Hildebrandt A, Zhou C. Segregation, integration, and balance of large-scale resting brain networks configure different cognitive abilities. Proc Natl Acad Sci. 2021;118:e2022288118.","journal-title":"Proc Natl Acad Sci"},{"key":"1943_CR130","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41386-022-01368-4","volume":"48","author":"SE Holmes","year":"2023","unstructured":"Holmes SE, Abdallah C, Esterlis I. Imaging synaptic density in depression. Neuropsychopharmacology. 2023;48:186\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"1943_CR131","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0028-3932(96)00110-8","volume":"35","author":"CE Elger","year":"1997","unstructured":"Elger CE, Grunwald T, Lehnertz K, Kutas M, Helmstaedter C, Brockhaus A, et al. Human temporal lobe potentials in verbal learning and memory processes. Neuropsychologia. 1997;35:657\u201367.","journal-title":"Neuropsychologia"},{"key":"1943_CR132","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jalz.2015.12.005","volume":"12","author":"MC De Wilde","year":"2016","unstructured":"De Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer\u2019s disease reveals selective molecular vesicular machinery vulnerability. Alzheimer\u2019s Dement. 2016;12:633\u201344.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1943_CR133","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00401-021-02282-7","volume":"141","author":"A Ramos-Miguel","year":"2021","unstructured":"Ramos-Miguel A, Jones AA, Petyuk VA, Barakauskas VE, Barr AM, Leurgans SE, et al. Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample. Acta Neuropathol. 2021;141:755\u201370.","journal-title":"Acta Neuropathol"},{"key":"1943_CR134","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/mrm.20023","volume":"51","author":"LM Parkes","year":"2004","unstructured":"Parkes LM, Rashid W, Chard DT, Tofts PS. Normal cerebral perfusion measurements using arterial spin labeling: reproducibility, stability, and age and gender effects. Magn Reson Med. 2004;51:736\u201343.","journal-title":"Magn Reson Med"},{"key":"1943_CR135","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1177\/0271678X19879230","volume":"40","author":"S Rossano","year":"2020","unstructured":"Rossano S, Toyonaga T, Finnema SJ, Naganawa M, Lu Y, Nabulsi N, et al. Assessment of a white matter reference region for 11C-UCB-J PET quantification. J Cereb Blood Flow Metab. 2020;40:1890\u2013901.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR136","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/cne.902740204","volume":"274","author":"R Napper","year":"1988","unstructured":"Napper R, Harvey R. Number of parallel fiber synapses on an individual Purkinje cell in the cerebellum of the rat. J Comp Neurol. 1988;274:168\u201377.","journal-title":"J Comp Neurol"},{"key":"1943_CR137","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jpsychires.2014.05.005","volume":"56","author":"L Wang","year":"2014","unstructured":"Wang L, Leonards CO, Sterzer P, Ebinger M. White matter lesions and depression: a systematic review and meta-analysis. J Psychiatr Res. 2014;56:56\u201364.","journal-title":"J Psychiatr Res"},{"key":"1943_CR138","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1001\/archpsyc.60.5.443","volume":"60","author":"KL Davis","year":"2003","unstructured":"Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003;60:443\u201356.","journal-title":"Arch Gen Psychiatry"},{"key":"1943_CR139","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.neubiorev.2009.10.012","volume":"34","author":"K Mahon","year":"2010","unstructured":"Mahon K, Burdick KE, Szeszko PR. A role for white matter abnormalities in the pathophysiology of bipolar disorder. Neurosci Biobehav Rev. 2010;34:533\u201354.","journal-title":"Neurosci Biobehav Rev"},{"key":"1943_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40478-018-0515-3","volume":"6","author":"SE Nasrabady","year":"2018","unstructured":"Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer\u2019s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6:1\u201310.","journal-title":"Acta Neuropathol Commun"},{"key":"1943_CR141","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.neuroimage.2010.02.033","volume":"51","author":"TR Barrick","year":"2010","unstructured":"Barrick TR, Charlton RA, Clark CA, Markus HS. White matter structural decline in normal ageing: a prospective longitudinal study using tract-based spatial statistics. Neuroimage. 2010;51:565\u201377.","journal-title":"Neuroimage"},{"key":"1943_CR142","unstructured":"Mansur A. Quantitative imaging of mitochondrial and synaptic function in the human brain with 18F-BCPP-EF, 11C-SA-4503, and 11C-UCB-J. Imperial College London. 2020."},{"key":"1943_CR143","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00259-018-4119-8","volume":"46","author":"M Koole","year":"2019","unstructured":"Koole M, van Aalst J, Devrome M, Mertens N, Serdons K, Lacroix B, et al. Quantifying SV2A density and drug occupancy in the human brain using [11 C] UCB-J PET imaging and subcortical white matter as reference tissue. Eur J Nucl Med Mol imaging. 2019;46:396\u2013406.","journal-title":"Eur J Nucl Med Mol imaging"},{"key":"1943_CR144","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/syn.20966","volume":"65","author":"RN Gunn","year":"2011","unstructured":"Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M, et al. Translational characterization of [11C] GSK931145, a PET ligand for the glycine transporter type 1. Synapse. 2011;65:1319\u201332.","journal-title":"Synapse"},{"key":"1943_CR145","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3233\/JAD-150687","volume":"50","author":"C Stockburger","year":"2016","unstructured":"Stockburger C, Miano D, Baeumlisberger M, Pallas T, Arrey TN, Karas M, et al. A mitochondrial role of SV2a protein in aging and Alzheimer\u2019s disease: studies with levetiracetam. J Alzheimer\u2019s Dis. 2016;50:201\u201315.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1943_CR146","unstructured":"Reichert JS. SV2A-just a synaptic vesicle protein? Unravelling the interaction of SV2A and mitochondria in the pathogenesis and therapy of Morbus Alzheimer. Dissertation, Mainz, Johannes Gutenberg-Universit\u00e4t Mainz, 2022;2022."},{"key":"1943_CR147","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1523\/JNEUROSCI.1316-16.2016","volume":"36","author":"KE Stahon","year":"2016","unstructured":"Stahon KE, Bastian C, Griffith S, Kidd GJ, Brunet S, Baltan S. Age-related changes in axonal and mitochondrial ultrastructure and function in white matter. J Neurosci. 2016;36:9990\u201310001.","journal-title":"J Neurosci"},{"key":"1943_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13041-022-00931-w","volume":"15","author":"BA Pazarlar","year":"2022","unstructured":"Pazarlar BA, Aripaka SS, Petukhov V, Pinborg L, Khodosevich K, Mikkelsen JD. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE). Mol Brain. 2022;15:1\u201310.","journal-title":"Mol Brain"},{"key":"1943_CR149","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.brainres.2019.03.021","volume":"1715","author":"A Vanoye-Carlo","year":"2019","unstructured":"Vanoye-Carlo A, G\u00f3mez-Lira G. Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development. Brain Res. 2019;1715:73\u201383.","journal-title":"Brain Res"},{"key":"1943_CR150","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3389\/fnmol.2017.00148","volume":"10","author":"O Bartholome","year":"2017","unstructured":"Bartholome O, Van den Ackerveken P, S\u00e1nchez Gil J, de la Brassinne Bonardeaux O, Leprince P, Franzen R, et al. Puzzling out synaptic vesicle 2 family members functions. Front Mol Neurosci. 2017;10:148.","journal-title":"Front Mol Neurosci"},{"key":"1943_CR151","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000501797","volume":"5","author":"CA Ross","year":"2019","unstructured":"Ross CA, Margolis RL. Research domain criteria: strengths, weaknesses, and potential alternatives for future psychiatric research. Complex Psychiatry. 2019;5:218\u201336.","journal-title":"Complex Psychiatry"},{"key":"1943_CR152","doi-asserted-by":"publisher","first-page":"27676","DOI":"10.1021\/acsomega.1c02433","volume":"6","author":"R Pracitto","year":"2021","unstructured":"Pracitto R, Wilcox KC, Lindemann M, Tong J, Zheng C, Li S, et al. Further Investigation of Synaptic Vesicle Protein 2A (SV2A) Ligands Designed for Positron Emission Tomography and Single-Photon Emission Computed Tomography Imaging: Synthesis and Structure\u2013Activity Relationship of Substituted Pyridinylmethyl-4-(3, 5-difluorophenyl) pyrrolidin-2-ones. ACS Omega. 2021;6:27676\u201383.","journal-title":"ACS Omega"},{"key":"1943_CR153","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1007\/s11307-019-01428-0","volume":"22","author":"S Patel","year":"2020","unstructured":"Patel S, Knight A, Krause S, Teceno T, Tresse C, Li S, et al. Preclinical in vitro and in vivo characterization of synaptic vesicle 2A\u2013targeting compounds amenable to F-18 labeling as potential PET radioligands for imaging of synapse integrity. Mol Imaging Biol. 2020;22:832\u201341.","journal-title":"Mol Imaging Biol"},{"key":"1943_CR154","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1177\/0271678X17724947","volume":"38","author":"SJ Finnema","year":"2018","unstructured":"Finnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, et al. Kinetic evaluation and test\u2013retest reproducibility of [11\u2009C] UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2\u2009A in humans. J Cereb Blood Flow Metab. 2018;38:2041\u201352.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR155","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.trci.2017.08.004","volume":"3","author":"MA Bahri","year":"2017","unstructured":"Bahri MA, Plenevaux A, Aerts J, Bastin C, Becker G, Mercier J, et al. Measuring brain synaptic vesicle protein 2\u2009A with positron emission tomography and [18\u2009F] UCB\u2010H. Alzheimer\u2019s Dement: Transl Res Clin Interventions. 2017;3:481\u20136.","journal-title":"Alzheimer\u2019s Dement: Transl Res Clin Interventions"},{"key":"1943_CR156","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11307-014-0820-6","volume":"17","author":"F Bretin","year":"2015","unstructured":"Bretin F, Bahri MA, Bernard C, Warnock G, Aerts J, Mestdagh N, et al. Biodistribution and radiation dosimetry for the novel SV2A radiotracer [18\u2009F] UCB-H: first-in-human study. Mol imaging Biol. 2015;17:557\u201364.","journal-title":"Mol imaging Biol"},{"key":"1943_CR157","unstructured":"Cai Z, Wu Y, Drake L, Naganawa M, Najafzadeh S, Pracitto R, et al. Evaluation of [18\u2009F] SynVesT-2 for imaging SV2A in the human brain: kinetics, test-retest reproducibility, and binding specificity. Soc Nuclear Med. 2021;62:44."},{"key":"1943_CR158","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1177\/0271678X19864081","volume":"40","author":"D Bertoglio","year":"2020","unstructured":"Bertoglio D, Verhaeghe J, Miranda A, Kertesz I, Cybulska K, Korat \u0160, et al. Validation and noninvasive kinetic modeling of [11\u2009C] UCB-J PET imaging in mice. J Cereb Blood Flow Metab. 2020;40:1351\u201362.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR159","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/molecules24091705","volume":"24","author":"ME Serrano","year":"2019","unstructured":"Serrano ME, Becker G, Bahri MA, Seret A, Mestdagh N, Mercier J, et al. Evaluating the in vivo specificity of [18\u2009F] UCB-H for the SV2A protein, compared with SV2B and SV2C in rats using microPET. Molecules 2019;24:1705.","journal-title":"Molecules"},{"key":"1943_CR160","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1177\/0271678X221101648","volume":"42","author":"D Bertoglio","year":"2022","unstructured":"Bertoglio D, Zajicek F, Lombaerde S, Miranda A, Stroobants S, Wang Y, et al. Validation, kinetic modeling, and test-retest reproducibility of [18\u2009F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2\u2009A in mice. J Cereb Blood Flow Metab. 2022;42:1867\u201378.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1943_CR161","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1006\/nimg.1996.0066","volume":"4","author":"AA Lammertsma","year":"1996","unstructured":"Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153\u20138.","journal-title":"Neuroimage"},{"key":"1943_CR162","doi-asserted-by":"crossref","unstructured":"Chen Z, Liao G, Wan N, He Z, Chen D, Tang Z, et al. Synaptic loss in spinocerebellar ataxia type 3 revealed by SV2A positron emission tomography. Movement Disorders. 2023;38:978\u201389.","DOI":"10.1002\/mds.29395"}],"updated-by":[{"DOI":"10.1038\/s41386-025-02087-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01943-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01943-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T18:32:57Z","timestamp":1743013977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-024-01943-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":162,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1038\/s41386-024-01943-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41386-025-02087-2","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41386-025-02087-2","URL":"https:\/\/doi.org\/10.1038\/s41386-025-02087-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OH has received investigator-initiated research funding from and\/or participated in advisory\/speaker meetings organised by Angellini, Autifony, Biogen, Boehringer-Ingelheim, Eli Lilly, Elysium, Heptares, Global Medical Education, Invicro, Jansenn, Karuna, Lundbeck, Merck, Neurocrine, Ontrack\/ Pangea, Otsuka, Sunovion, Recordati, Roche, Rovi and Viatris\/Mylan. He was previously a part-time employee of Lundbeck A\/v. OH has a patent for the use of dopaminergic imaging. RC, FET and JM have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}